Compare Mattel Inc (MAT) vs TG Therapeutics Inc (TGTX) Price & Performance

Mattel (MAT) trades at $14.76, up 0.14%, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with a 10% revenue beat but an earnings miss, reflecting margin pressure from higher costs. Valuation appears reasonable with a P/E of 11.22 and P/S of 0.84, while profitability metrics like a 7.78% net margin and 20.5% ROE remain solid. Recent news highlights growth from toy-based films and adult collectors, though competitive and cost challenges persist.

The outlook is cautiously optimistic, supported by brand strength and entertainment initiatives, but near-term earnings volatility and discretionary spending sensitivity pose risks. Analyst consensus leans Buy with a $14.00 price target, suggesting modest upside potential from current levels amid ongoing execution scrutiny.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.